Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: real-world multicenter data

726 early TNBC patients (Neo-Real cohort), neoadjuvant pembrolizumab + chemo, analysis by germline BRCA status

726 consecutive patients treated for early TNBC with neoadjuvant pembrolizumab + chemotherapy in the multicenter Neo-Real/GBECAM-0123 cohort are analyzed by germline BRCA1/2 status. Carriers of germline BRCA1/2 pathogenic variants show higher pathological complete response (pCR) rates than non-carriers, confirming in real-world data the synergistic effect between germline homologous recombination deficiency and immunotherapy. These data guide preferential pembrolizumab indication in germline BRCA TNBC.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Real-world data on pembrolizumab + chemo in germline BRCA TNBC are important because randomized trials (KEYNOTE-522) reported overall results without systematic stratification by germline status. This work partially fills this gap and reinforces patient selection of gBRCA for neoadjuvant pembrolizumab protocols.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10